Table 2.
Events associated with the use of selective estrogen receptor modulators (SERMs)
| Study, year | Type of study | Patients (n) | Assessed/ compared SERMs | Breast cancer | VTE | CVA | CAD |
|---|---|---|---|---|---|---|---|
| STAR, Vogel et al.11 2006 | Clinical trial | 19,747 postmenopausal women | Tamoxifen and raloxifene | Risk reduction of 50% (in situ - tamoxifen and raloxifene and invasive- tamoxifen) | Increase, raloxifene < tamoxifen of 30% | Reduction (tamoxifen and raloxifene) | Increase (tamoxifen and raloxifene) |
| MORE, Cauley et al.13 2001 | Clinical trial | 7,705 postmenopausal women | Raloxifene and placebo | Risk reduction of 72% after 4 years | Increase | Neutral | Neutral |
| CORE / Martino et al.14 / 2004 | Clinical trial | 5,213 postmenopausal women | Raloxifene and placebo | Risk reduction of 59% | Increase | ||
| NSABP / Fisher et al.9 / 1998 | Clinical trial | 13,388 at risk for breast cancer | Tamoxifen and placebo | Risk reduction of 49% | Increase | Increase | Neutral |
| IBIS-1 / Cuzick et al.8 / 2002 | Clinical trial | 7,152 at risk of breast cancer | Tamoxifen and placebo | Risk reduction of 32% | Increase | Neutral | Neutral |
| RUTH / Barret-Connor et al.21 / 2006 | Clinical trial | 10,101 postmenopausal women | Raloxifene and placebo | Invasive cancer risk reduction of 55% | Increase of 44% | Increase of 49% | Neutral |
VTE: venous thromboembolism; CAD: coronary artery disease.